Ionis Pharmaceuticals, Inc. IONS
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing position can be maintained pending further launch data and regulatory decisions.
Strong pipeline and solid cash position are still balanced by high execution risk following the TRYNGOLZA guidance cut which supports the hold signal.
The market reacted negatively to the lowered TRYNGOLZA sales guidance and increased uncertainty around commercial execution.
HOLD is the call. Neutral is the market mood. High risk means a lot can go wrong.
Latest change
- 10 Nov 2026 — The report shows lower revenue and reduced TRYNGOLZA guidance driving increased commercialization uncertainty.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (4) — follow the company freeAbout the company
Ionis Pharmaceuticals develops and commercializes antisense oligonucleotide medicines for neurological, metabolic and cardiovascular diseases. The company is transitioning from a royalty-based model to own commercialization with several recently launched products. Operations remain loss-making but supported by a strong cash position and pipeline.
Bull case
EU approval for TRYNGOLZA and positive phase 3 data for ulefnersen and sifaxersen bolster pipeline value.
Bear case
Lowered TRYNGOLZA guidance and greater uncertainty around in-house commercialization raise execution risk.
Why this signal
Strong pipeline and solid cash position are still balanced by high execution risk following the TRYNGOLZA guidance cut which supports the hold signal.
Recent news
Ionis reported Q3 2026 revenue of 243 MUSD but lowered full-year TRYNGOLZA guidance to approximately 50 MUSD from 100–110 MUSD. The stock fell 21 % to 31 USD on elevated volume and an investigation into possible misleading information has been initiated.